Responses to angiotensin peptides are mediated by AT1 receptors in the rat

American Journal of Physiology - Endocrinology and Metabolism

Volumn 274, Issue 1 37-1, 1998, Pages

  Champion, Hunter C ^a   Czapla, Marc A ^a   Kadowitz, Philip J ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic system; Angiotensin II, III, IV; Arterial pressure; Candesartan; Hindquarters vascular bed; PD 123,319; Vasoconstrictor vasodilator responses

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN;

ADRENERGIC NERVE; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; DRUG RECEPTOR BINDING; FEMALE; HEMODYNAMIC MONITORING; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION;

EID: 0031934028     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1998.274.1.e115     Document Type: Article

References (31)

1. Bauer, P. H., A. T. Chiu, and J. C. Garrison. DuP 753 can antagonize the effects of angiotensin II in rat liver. Mol. Pharmacol. 39: 579-585, 1991.
2. 2 subtype. J. Med. Chem. 34: 3248-3260, 1991.
3. Bottari, S. P., M. DeGasparo, U. M. Stackelings, and N. R. Levens. Angiotensin II receptor subtypes: characterization, signalling mechanisms, and possible physiological implications. Front. Neuroendocrinol. 14: 134-171, 1993.
4. Campbell, W. J., Jr., J. A. Donohue, and L. H. Duket. Alterations in responses to bradykinin, angiotensin I, and angiotensin II during the induction phase of one-kidney, one-wrapped hypertension and associated arterial disease in rabbits. Am. J. Pathol. 98: 457-484, 1980.
5. Champion, H. C., E. A. Garrison, L. S. Estrada, J. M. Potter, and P. J. Kadowitz. Analysis of responses to angiotensin I and angiotensin I-(3-10) in the mesenteric vascular bed of the cat. Eur. J. Pharmacol. 309: 251-259, 1996.
6. 1 receptors. Hypertension 30:1060-1066, 1997.
7. Chang, R. S. L., and V. J. Lotti. Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol. Pharmacol. 37: 347-351, 1990.
8. Cheng, D. Y., B. J. DeWitt, E. L. Dent, B. D. Nossaman, and P. J. Kadowitz. Analysis of responses to angiotensin IV in the pulmonary vascular bed of the cat. Eur. J. Pharmacol. 261: 223-227, 1994.
9. Cheng, D. Y., B. J. DeWitt, T. J. McMahon, and P. J. Kadowitz. Comparison of pressor responses to angiotensin I, II, and III in pulmonary vascular bed of cats. Am. J. Physiol. 266 (Heart Circ. Physiol. 35): H2247-H2255, 1994.
10. Chiu, A. T., W. F. Herblin, D. E. McCall, R. J. Ardecky, D. J. Carini, J. V. Duncia, L. J. Pease, P. C. Wong, R. R. Wexler, A. L. Johnson, and P. M. B. W. M. Timmermans. Identification of angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 165: 196-203, 1989.
11. De Gasparo, M., S. Whitebread, M. Mele, A. S. Motani, P. J. Whitcombe, H. Ramjoue, and B. Kamber. Biochemical characterization of two angiotensin II receptor subtypes in the rat. J. Cardiovasc. Pharmacol. 16: S31-S35, 1990.
12. DiSalvo, J., and C. B. Montefusco. Conversion of angiotensin I to angiotensin II in the canine mesenteric circulation. Am. J. Physiol. 221: 1576-1579, 1971.
13. Dudley, D. T., R. L. Panek, T. C. Major, G. H. Lu, R. F. Burns, B. A. Klinkefus, J. C. Hodges, and R. E. Weishaar. Subclasses of angiotensin II binding sites and their functional significance. Mol. Pharmacol. 38: 370-377, 1990.
14. Fleming, J. T., and I. G. Joshua. Mechanism of biphasic arteriolar response to angiotensin II. Am. J. Physiol. 247 (Heart Circ. Physiol. 16): H88-H94, 1984.
15. Garrison, E. A., and P. J. Kadowitz. Analysis of responses to angiotensin I-(3-10) in the hindlimb vascular bed of the cat. Am. J. Physiol. 270 (Heart Circ. Physiol. 39): H1172-H1177, 1996.
16. Garrison, E. A., J. A. Santiago, and P. J. Kadowitz. Analysis of responses to angiotensin peptides in the hindquarters vascular bed of the cat. Am. J. Physiol. 268 (Heart Circ. Physiol. 37): H2418-H2425, 1995.
17. Mizuno, K., S. Nimura, M. Tani, I. Saito, H. Sanada, M. Takahashi, K. Skazaki, M. Yamaguchi, and S. Fukuchi. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci. 51: PL183-PL187, 1992.
18. Navar, L. G., E. W. Inscho, D. S. A. Majid, J. D. Imig, L. M. Harrison-Bernard, and K. D. Mitchell. Paracrine regulation of the renal microcirculation. Physiol. Rev. 76: 425-536, 1996.
19. Noda, M., Y. Shibouta, Y. Inada, M. Ojima, T. Wada, T. Sanada, J. Kubo, Y. Kohara, T. Naka, and K. Nishikawa. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem. Pharmacol. 46: 311-318, 1993.
20. Osei, S. Y., R. K. Minkes, J. A. Bellan, and P. J. Kadowitz. Analysis of the inhibitory effects of DuP753 and EXP 3174 on responses to angiotensin II in the feline hindquarters vascular bed. J. Pharmacol. Exp. Ther. 264: 1104-1112, 1993.
21. Peach, M. J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 57: 313-370, 1977.
22. Regoli, D., W. K. Park, and N. D. Rioux. Pharmacology of angiotensin. Pharmacol. Rev. 26: 69-123, 1974.
23. Rowe, B. P., and A. Nasjeletti. Biphasic blood pressure response to angiotensin II in the conscious rabbit: relation to prostaglandins. J. Pharmacol. Exp. Ther. 255: 559-563, 1983.
24. Scheuer, D. A., and M. H. Perrone. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am. J. Physiol. 264 (Regulatory Integrative Comp. Physiol. 33): R917-R923, 1993.
25. Sechi, L. A., E. F. Grady, C. A. Griffin, J. E. Kalikyak, and M. Schambelan. Distribution of angiotensin II receptor subtypes in a rat and human kidney. Am. J. Physiol. 262 (Renal Fluid Electrolyte Physiol. 31): F236-F240, 1992.
26. Shibouta, Y., Y. Inada, M. Ojima, T. Wada, M. Noda, T. Sanada, K. Kubo, Y. Kohara, T. Naka, and K. Nishikawa. Pharmacological profile of a highly potent and long-lasting angiotensin II receptor antagonist, 2-ethoxy-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (+-)-1-(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-{[2′-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate (TCV-116). J. Pharmacol. Exp. Ther. 266: 114-120, 1993.
27. Timmermans, P. B. M. W. M., P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. M. Saye, and R. D. Smith. Angiotensin II receptor and angiotensin II receptor antagonists. Pharmacol. Rev. 45: 205-251, 1993.
28. Tofovic, S. P., A. S. Pong, and E. K. Jackson. Effect of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension 18: 774-782, 1991.
29. Wada, T., Y. Inada, T. Sanada, M. Ojima, Y. Shibouta, M. Noda, and K. Nishikawa. Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone. Eur. J. Pharmacol. 253: 27-34, 1994.
30. Wong, P. C., S. D. Hart, J. V. Duncia, and P. B. M. W. M. Timmermans. Nonpeptide angiotensin II receptor antagonists: studies with DuP 753 and EXP 3174 in dogs. Eur. J. Pharmacol. 202: 323-330, 1991.
31. Wong, P. C., S. D. Hart, A. M. Zaspel, A. T. Chiu, R. J. Ardecky, R. D. Smith, and P. B. M. W. M. Timmermans. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753(AII-1) and PD123177(AII-2). J. Pharmacol. Exp. Ther. 255: 584-592, 1990.